Chemotherapy in colorectal cancer.
198 patients with colorectal carcinoma were given chemotherapy. Adjuvant chemotherapy was applied to 73 patients, postoperatively, with Dukes A, B, C disease. 125 patients were Dukes D. The four different chemotherapy regimens comprised fluorouracil (5-FU) alone, 5-FU plus levamisole, 5-FU plus mitomycin-C and 5-FU plus adriamycin. Median survival was 18 months in the adjuvant group, with 67%, 30% and 19% of patients alive at the end of 1st, 2nd and 3rd years. 5-FU plus adriamycin and 5-FU plus levamisole give better survival rates. Median survival was 7 months in the metastatic group and only 23% are alive at the end of the first year. Favorable results were observed only with 5-FU plus adriamycin. Even though chemotherapy seems to be of limited value in advanced colorectal cancer, survival and life quality improve when it is given on an adjuvant basis.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012004:Rectal Neoplasms / Q000188:drug therapy*
D005472:Fluorouracil